CoChat
Sign Up
PreprintCited by 298SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India

Open access
Dhar, Mahesh S, Marwal, Robin, Radhakrishnan, VS, Ponnusamy, Kalaiarasan, Jolly, Bani, Bhoyar, Rahul C., Sardana, Viren, Naushin, Salwa, Rophina, Mercy, Mellan, Thomas A, Mishra, Swapnil, Whittaker, Charles, Fatihi, Saman, Datta, Meena, Singh, Priyanka, Sharma, Uma, Ujjainiya, Rajat, Batheja, Nitin, Divakar, Mohit Kumar, Singh, Manoj K, Imran, Mohamed, Senthivel, Vigneshwar, Maurya, Ranjeet, Jha, Neha, Mehta, Priyanka, Vivekanand, A, Sharma, Pooja, Arvinden, VR, Chaudhary, Urmila, Soni, Namita, Thukral, Lipi, Flaxman, Seth, Bhatt, Samir, Pandey, Rajesh, Dash, Debasis, Faruq, Mohammed, Lall, Hemlata, Gogia, Hema, Madan, Preeti, Kulkarni, Sanket, Chauhan, Himanshu, Sengupta, Shantanu, Kabra, Sandhya, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Gupta, Ravindra K., Singh, Sujeet K, Agrawal, Anurag, Rakshit, Partha·2021·Science
DOI 10.1101/2021.06.02.21258076PMC PMC7612010

Preprint — published as 10.1126/science.abj9932

Open this paper in CoChat — free account

Abstract

Delhi, the national capital of India, has experienced multiple SARS-CoV-2 outbreaks in 2020 and reached a population seropositivity of over 50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and partial reduction of immunity elicited by prior infection (median estimates; ×1.5-fold, 20% reduction). Seropositivity of an employee and family cohort increased from 42% to 86% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi. One-Sentence Summary: Delhi experienced an overwhelming surge of COVID-19 cases and fatalities peaking in May 2021 as the highly transmissible and immune evasive Delta variant replaced the Alpha variant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.06.02.21258076

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Multiple surges of SARS-CoV-2 infections in Delhi with an overwhelming outbreak in April and May 2021. (A) Weekly tests, confirmed cases, and test positivity rate in Delhi from April 2020 to June 2021. Sample collection period for CSIR serosurveys is marked as P1 to P3. (B) Number of hospitalizations and ICU admissions plotted on a daily basis from June 2020 to June 2021. The arrow marks the possible saturation of ICU capacity (3). (C) Daily cases and daily deaths from January 2021 to June 2021. (D) Time-advanced and scaled cumulative cases, fitted to cumulative deaths. Time advancement of cumulative reported cases by 8 days was done for maximal coincidence with scaled cumulative deaths. Case fatality ratio = averaged scaling factor (cumulative deaths / time-advanced cumulative cases). Mean ± SD, 0.019 ± 0.003.
Fig. 1. Multiple surges of SARS-CoV-2 infections in Delhi with an overwhelming outbreak in April and May 2021. (A) Weekly tests, confirmed cases, and test positivity rate in Delhi from April 2020 to June 2021. Sample collection period for CSIR serosurveys is marked as P1 to P3. (B) Number of hospitalizations and ICU admissions plotted on a daily basis from June 2020 to June 2021. The arrow marks the possible saturation of ICU capacity (3). (C) Daily cases and daily deaths from January 2021 to June 2021. (D) Time-advanced and scaled cumulative cases, fitted to cumulative deaths. Time advancement of cumulative reported cases by 8 days was done for maximal coincidence with scaled cumulative deaths. Case fatality ratio = averaged scaling factor (cumulative deaths / time-advanced cumulative cases). Mean ± SD, 0.019 ± 0.003.CC BY · PubMed Central
Fig. 2. Serological estimates of prior infections, preexisting immunity, and new infections for the April and May 2021 outbreak. (A) Seropositivity in the CSIR cohort, subdivided by nature of employment and use of public transport, plotted for different time periods (phase I to phase III, proportion ± 95% CI). Details are provided in table S1. (B) Variability and temporal decline in neutralization capacity estimated by sVNT assay between phases I and II (n = 52 subjects). (C) Serial antibody concentration measurements in initially seropositive subjects (n = 91). Pattern suggestive of reinfections is shown (decline followed by rise, n = 25). (D) Remaining data (n = 66 subjects), with four indeterminate reinfection cases indicated with arrows. Antibody concentration is reported in multiples of the assay cutoff index value (CoI).
Fig. 2. Serological estimates of prior infections, preexisting immunity, and new infections for the April and May 2021 outbreak. (A) Seropositivity in the CSIR cohort, subdivided by nature of employment and use of public transport, plotted for different time periods (phase I to phase III, proportion ± 95% CI). Details are provided in table S1. (B) Variability and temporal decline in neutralization capacity estimated by sVNT assay between phases I and II (n = 52 subjects). (C) Serial antibody concentration measurements in initially seropositive subjects (n = 91). Pattern suggestive of reinfections is shown (decline followed by rise, n = 25). (D) Remaining data (n = 66 subjects), with four indeterminate reinfection cases indicated with arrows. Antibody concentration is reported in multiples of the assay cutoff index value (CoI).CC BY · PubMed Central
Fig. 3. Genomic-epidemiologic correlations. (A) Time trends of Ct values (mean ± SE) and high viral load samples (proportion ± SE) for Orf1 gene (E gene data, fig. S1). (B) Smoothed graph of main lineages in Delhi from March 2020 to May 2021 in biweekly increments. New cases and TPR are aligned and plotted on the same timeline. (C) Phylogenetic analysis for variant of concern (VOC) strains between Delhi and states (Punjab and Maharashtra) with known VOC outbreaks before April 2021. Further analysis suggesting a superspreading event for Alpha is shown in fig. S3. (D to F) Month-wise proportions of different lineages (n > 3 sequenced samples) in states surrounding Delhi. Additional data are shown in figs. S4 and S5.
Fig. 3. Genomic-epidemiologic correlations. (A) Time trends of Ct values (mean ± SE) and high viral load samples (proportion ± SE) for Orf1 gene (E gene data, fig. S1). (B) Smoothed graph of main lineages in Delhi from March 2020 to May 2021 in biweekly increments. New cases and TPR are aligned and plotted on the same timeline. (C) Phylogenetic analysis for variant of concern (VOC) strains between Delhi and states (Punjab and Maharashtra) with known VOC outbreaks before April 2021. Further analysis suggesting a superspreading event for Alpha is shown in fig. S3. (D to F) Month-wise proportions of different lineages (n > 3 sequenced samples) in states surrounding Delhi. Additional data are shown in figs. S4 and S5.CC BY · PubMed Central
Fig. 4. Estimates of the epidemiological characteristics of the Delta variant. Values were inferred from a two-category Bayesian transmission model fitted to mortality, serosurvey, and genomic data from Delhi, India. (A) Joint posterior distribution, with isoclines corresponding to the 90% and 50% enclosures of posterior density of the Delta variant immune escape and transmissibility increase relative to non-Delta categories. Immune escape has a median of 20% with 50% Bayesian credible interval (bCI) of 10 to 50%, and transmissibility has a median increase of 1.5 with 50% bCI of 1.3 to 1.7. (B) Delta fraction over time, inferred by the model. Black dots represent genome sampling data points, with exact binomial confidence intervals. (C) Serosurvey data (black dots) and inferred cumulative incidence for Delta and non-Delta variant categories. (D) Mortality data (black dots) and inferred deaths assuming 50% underreporting. Other underascertainment scenarios are presented in the supplementary materials.
Fig. 4. Estimates of the epidemiological characteristics of the Delta variant. Values were inferred from a two-category Bayesian transmission model fitted to mortality, serosurvey, and genomic data from Delhi, India. (A) Joint posterior distribution, with isoclines corresponding to the 90% and 50% enclosures of posterior density of the Delta variant immune escape and transmissibility increase relative to non-Delta categories. Immune escape has a median of 20% with 50% Bayesian credible interval (bCI) of 10 to 50%, and transmissibility has a median increase of 1.5 with 50% bCI of 1.3 to 1.7. (B) Delta fraction over time, inferred by the model. Black dots represent genome sampling data points, with exact binomial confidence intervals. (C) Serosurvey data (black dots) and inferred cumulative incidence for Delta and non-Delta variant categories. (D) Mortality data (black dots) and inferred deaths assuming 50% underreporting. Other underascertainment scenarios are presented in the supplementary materials.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 1

  1. Ferreira, Isabella et al. SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion. The Journal of infectious diseases, jiab368.

Cited by

Sorted by citations

Items 201–298 of 298

Related

See all

Metadata

Authors
Dhar, M. S., Marwal, R., Radhakrishnan, V., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Batheja, N., Divakar, M. K., Singh, M. K., Imran, M., Senthivel, V., Maurya, R., Jha, N., Mehta, P., Vivekanand, A., Sharma, P., Arvinden, V., Chaudhary, U., Soni, N., Thukral, L., Flaxman, S., Bhatt, S., Pandey, R., Dash, D., Faruq, M., Lall, H., Gogia, H., Madan, P., Kulkarni, S., Chauhan, H., Sengupta, S., Kabra, S., The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Gupta, R. K., Singh, S. K., Agrawal, A., & Rakshit, P.
Affiliations
  • National Center for Disease Control (IN)
  • Institute of Genomics and Integrative Biology (IN)
  • Imperial College London (GB)
  • University of Copenhagen (DK)
  • University of Cambridge (GB)
Corresponding author
  • Dhar, Mahesh S
  • Marwal, Robin
  • Radhakrishnan, VS
  • Ponnusamy, Kalaiarasan
  • Jolly, Bani
  • Bhoyar, Rahul C.
  • Agrawal, Anurag
  • Rakshit, Partha
ORCID
Venue
Science
Publisher
openRxiv
Published
2021-06-03
Volume
374
Issue
6570
Pages
995-999
ISSN
0036-8075 (ISSN-L)
DOI
10.1101/2021.06.02.21258076
PMC
PMC7612010
OpenAlex
W3205588626
Cited by
296
References
43
Citations by year
2026: 7 · 2025: 19 · 2024: 38 · 2023: 65 · 2022: 115 · 2021: 51
FWCI
21.30
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Greater South Information System
Funders
  • Wellcome Trust (108082/A/15/Z, 108082)
  • Novo Nordisk Fonden (NNF20OC0059309)
  • Medical Research Council (MR/R015600/1, MC_PC_19012)
  • Engineering and Physical Sciences Research Council (EP/V002910/1, EP/V002910/2)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, Delta variant, B.1.1.7 Alpha variant, COVID-19 outbreak, Delhi, genomic profiling, epidemiology, transmissibility, immune evasion, reinfection, seroprevalence, antibody response, Bayesian model
MeSH terms
Reinfection, COVID-19, Adolescent, Adult, Child, Humans, India, Phylogeny, Seroepidemiologic Studies, Genome, Viral, Molecular Epidemiology, Young Adult, Immune Evasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review